← BeyondSpring Inc. (BYSI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BeyondSpring Inc. (BYSI)
Pharmaceutical Preparations · market cap $31M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
4
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
BeyondSpring Inc. (BYSI) is a micro-cap pharmaceutical company with a market cap of approximately $55M and a share price near $1.33. Its pipeline is anchored by plinabulin, a small molecule being evaluated in Phase 3 trials for non-small cell lung cancer (in combination with docetaxel) and chemotherapy-induced neutropenia (CIN), alongside a Phase 3 nitric oxide program for bronchiolitis. With only $4.0M in cash and a 3.7-month runway, the company faces acute near-term financing pressure.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2026-11-15 (est.)Phase 2 · Plinabulinimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Docetaxel + Plinabulin (DP) | Phase 3 | Non-Small Cell Lung Cancer |
| Plinabulin | Phase 3 | Chemotherapy-induced Neutropenia |
| Pegfilgrastim | Phase 3 | Chemotherapy-induced Neutropenia |
| Nitric Oxide | Phase 3 | Bronchiolitis |
Price & technical context
3-month
-55.3%
6-month
-53.8%
12-month
-55.3%
52-wk range
$0.60–$2.35
vs 50-day MA
-1.2%
vs 200-day MA
-42.5%
Realized vol
103.3%
Max drawdown
-82.4%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BYSI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.